Prospective Double-Blind Randomized Study of Single Dose Bone Marrow-Derived Mesenchymal Stromal Cells versus Placebo for Steroid-Refractory Acute Graft-Versus-Host Disease
Although only a few patients were included in the trial, a single dose of BM-MSCs did not seem to be an effective therapy for steroid-refractory acute GVHD.
Authors
- Behnam Sadeghi (ORCID: https://orcid.org/0000-0002-8721-0400)
- Olle Ringdén (ORCID: https://orcid.org/0000-0002-6092-1536)
- Mats Remberger (ORCID: https://orcid.org/0000-0003-0520-4312)
- Lena Klingspor (ORCID: https://orcid.org/0000-0001-8259-3556)
- Magnus Westgren (ORCID: https://orcid.org/0000-0003-1174-2184)
- Guido Moll (ORCID: https://orcid.org/0000-0001-6173-5957)
- Jonas Mattsson (ORCID: https://orcid.org/0000-0002-2163-6644)
- Britt Gustafsson (ORCID: https://orcid.org/0000-0002-7080-5053)
Institutions
- Uppsala University Hospital (SE)
- Princess Margaret Cancer Centre (CA)
- Karolinska Institutet (SE)
- Humboldt-Universität zu Berlin (DE)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Transfusion Medicine and Hemotherapy
- Published
- 2025-10-24
- DOI
- https://doi.org/10.1159/000549174
- Primary Topic
- Mesenchymal stem cell research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Commission
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung
- Cancerfonden
- Karolinska Institutet
- Vetenskapsrådet
- Cancerföreningen i Stockholm
- Berlin-Brandenburg School for Regenerative Therapies